Corporate & Investor Presentation

Big data analysis drives insights for treatment of central sleep apnea Patients with treatment-emergent central sleep apnea (CSA) are 2x more likely to terminate therapy • Opportunity to rethink conventional therapeutic options Minimize risk of therapy termination through early diagnosis • Regularly monitor patients to support adherence to treatment 100 50 Analysis of ~200k CSA patients 22% increase in adherence CMS adherence on CPAP prior to switching 62.7% CMS adherence after switching to ASV 76.6% Switching from therapy CPAP to ASV improved relative adherence by 22% Patients who switched from CPAP to ASV had fewer apneas and hyponeas during sleep 47 2021 ResMed | Corporate & Investor Presentation - updated 29APR21 AM CHEST Journal ResMed

View entire presentation